vs
Side-by-side financial comparison of CENTRAL PACIFIC FINANCIAL CORP (CPF) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $72.9M, roughly 1.4× CENTRAL PACIFIC FINANCIAL CORP). CENTRAL PACIFIC FINANCIAL CORP runs the higher net margin — 28.4% vs -29.4%, a 57.8% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs 6.0%).
Central Pacific Bank (CPB) is an American regional commercial bank located throughout the state of Hawaii.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
CPF vs TWST — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $72.9M | $103.7M |
| Net Profit | $20.7M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | — | -31.7% |
| Net Margin | 28.4% | -29.4% |
| Revenue YoY | 6.0% | 16.9% |
| Net Profit YoY | 16.7% | 3.4% |
| EPS (diluted) | $0.78 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $72.9M | — | ||
| Q4 25 | $76.3M | $103.7M | ||
| Q3 25 | $74.8M | — | ||
| Q2 25 | $72.8M | — | ||
| Q1 25 | $68.8M | — | ||
| Q4 24 | $58.4M | — | ||
| Q3 24 | $66.6M | — | ||
| Q2 24 | $64.0M | — |
| Q1 26 | $20.7M | — | ||
| Q4 25 | $22.9M | $-30.5M | ||
| Q3 25 | $18.6M | — | ||
| Q2 25 | $18.3M | — | ||
| Q1 25 | $17.8M | — | ||
| Q4 24 | $11.3M | — | ||
| Q3 24 | $13.3M | — | ||
| Q2 24 | $15.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 37.0% | -31.7% | ||
| Q3 25 | 31.6% | — | ||
| Q2 25 | 32.8% | — | ||
| Q1 25 | 32.8% | — | ||
| Q4 24 | 23.0% | — | ||
| Q3 24 | 25.6% | — | ||
| Q2 24 | 32.2% | — |
| Q1 26 | 28.4% | — | ||
| Q4 25 | 30.0% | -29.4% | ||
| Q3 25 | 24.8% | — | ||
| Q2 25 | 25.1% | — | ||
| Q1 25 | 25.8% | — | ||
| Q4 24 | 19.4% | — | ||
| Q3 24 | 20.0% | — | ||
| Q2 24 | 24.7% | — |
| Q1 26 | $0.78 | — | ||
| Q4 25 | $0.85 | $-0.50 | ||
| Q3 25 | $0.69 | — | ||
| Q2 25 | $0.67 | — | ||
| Q1 25 | $0.65 | — | ||
| Q4 24 | $0.42 | — | ||
| Q3 24 | $0.49 | — | ||
| Q2 24 | $0.58 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $197.9M |
| Total DebtLower is stronger | $76.5M | — |
| Stockholders' EquityBook value | $593.9M | $456.1M |
| Total Assets | $7.5B | $638.1M |
| Debt / EquityLower = less leverage | 0.13× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $197.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $76.5M | — | ||
| Q4 25 | $76.5M | — | ||
| Q3 25 | $131.5M | — | ||
| Q2 25 | $131.5M | — | ||
| Q1 25 | $131.4M | — | ||
| Q4 24 | $156.3M | — | ||
| Q3 24 | $156.3M | — | ||
| Q2 24 | $156.2M | — |
| Q1 26 | $593.9M | — | ||
| Q4 25 | $592.6M | $456.1M | ||
| Q3 25 | $588.1M | — | ||
| Q2 25 | $568.9M | — | ||
| Q1 25 | $557.4M | — | ||
| Q4 24 | $538.4M | — | ||
| Q3 24 | $543.7M | — | ||
| Q2 24 | $518.6M | — |
| Q1 26 | $7.5B | — | ||
| Q4 25 | $7.4B | $638.1M | ||
| Q3 25 | $7.4B | — | ||
| Q2 25 | $7.4B | — | ||
| Q1 25 | $7.4B | — | ||
| Q4 24 | $7.5B | — | ||
| Q3 24 | $7.4B | — | ||
| Q2 24 | $7.4B | — |
| Q1 26 | 0.13× | — | ||
| Q4 25 | 0.13× | — | ||
| Q3 25 | 0.22× | — | ||
| Q2 25 | 0.23× | — | ||
| Q1 25 | 0.24× | — | ||
| Q4 24 | 0.29× | — | ||
| Q3 24 | 0.29× | — | ||
| Q2 24 | 0.30× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-24.8M |
| Free Cash FlowOCF − Capex | — | $-34.8M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | — | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $97.5M | $-24.8M | ||
| Q3 25 | $22.2M | — | ||
| Q2 25 | $34.3M | — | ||
| Q1 25 | $20.4M | — | ||
| Q4 24 | $90.5M | — | ||
| Q3 24 | $21.3M | — | ||
| Q2 24 | $25.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | $92.3M | $-34.8M | ||
| Q3 25 | $21.4M | — | ||
| Q2 25 | $32.3M | — | ||
| Q1 25 | $19.6M | — | ||
| Q4 24 | $75.4M | — | ||
| Q3 24 | $15.6M | — | ||
| Q2 24 | $21.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | 121.0% | -33.5% | ||
| Q3 25 | 28.6% | — | ||
| Q2 25 | 44.3% | — | ||
| Q1 25 | 28.4% | — | ||
| Q4 24 | 129.2% | — | ||
| Q3 24 | 23.5% | — | ||
| Q2 24 | 33.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 6.8% | 9.6% | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 2.7% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 25.8% | — | ||
| Q3 24 | 8.5% | — | ||
| Q2 24 | 7.3% | — |
| Q1 26 | — | — | ||
| Q4 25 | 4.26× | — | ||
| Q3 25 | 1.20× | — | ||
| Q2 25 | 1.88× | — | ||
| Q1 25 | 1.15× | — | ||
| Q4 24 | 7.98× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.64× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CPF
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
